Anemia in renal disease: Diagnosis and management

Blood Reviews

Volumn 24, Issue 1, 2010, Pages 39-47

  Lankhorst, Christina E ^a   Wish, Jay B ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Anemia; Chronic kidney disease; Erythropoiesis stimulating agents; Erythropoietin; Erythropoietin resistance; Ferritin; Iron deficiency; Transferrin saturation

Indexed keywords

ANDROGEN; ANTIANEMIC AGENT; ASCORBIC ACID; CARNITINE; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; ERYTHROPOIETIN; FERRIC HYDROXIDE SUCROSE; FERRITIN; FERROUS GLUCONATE; FERROUS SULFATE; FERUMOXYTOL; FUMARIC ACID; GLUCONIC ACID; HEMOGLOBIN; IMMUNOSUPPRESSIVE AGENT; IRON; IRON DEXTRAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADJUVANT THERAPY; ANAPHYLAXIS; ANEMIA; ARTICLE; BLOOD VESSEL INJURY; CAUSAL ATTRIBUTION; CELL DAMAGE; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE COUNT; EVALUATION; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HUMAN; HYPERTENSION; HYPERTENSION ENCEPHALOPATHY; HYPOTENSION; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON THERAPY; KIDNEY DISEASE; KIDNEY TUBULE DAMAGE; LABORATORY TEST; MORBIDITY; NAUSEA; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PURE RED CELL ANEMIA; RETICULOCYTE COUNT; SEIZURE; SIDE EFFECT; TRANSFERRIN BLOOD LEVEL; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; VOMITING;

ANEMIA; DISEASE MANAGEMENT; HEMATINICS; HUMANS; KIDNEY DISEASES;

EID: 71649083056     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2009.09.001     Document Type: Article

References (75)

1. National Kidney Foundation. Chronic kidney disease. ; 2009 [accessed 7.07.09].
2. Weiner D.E., Tighiouart H., Vlagopoulos P.T., et al. Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol 16 (2005) 1803-1810
3. World Health Organization. Database of anemia. Worldwide prevalence of anaemia 1993-2005. ; 2009 [accessed 7.07.09].
4. Hsu C.Y., McCulloch C.E., and Curhan G.C. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the third national health and nutrition examination survey. J Am Soc Nephrol 13 (2002) 504-510
5. Astor B.C., Muntner P., Levin A., Eustace J.A., and Coresh J. Association of kidney function with anemia: the third national health and nutrition examination survey (1988-1994). Arch Intern Med 162 (2002) 1401-1408
6. Fehally J., Floege J., and Johnson R. Comprehensive clinical nephrology (2003), Mosby Elsevier, Philadelphia p. 853-60
7. Eckardt K.U. Erythropoietin: oxygen-dependent control of erythropoiesis and its failure in renal disease. Nephron 67 (1994) 7-23
8. Eschbach J.W., Adamson J.W., and Cook J.D. Disorders of red cell production in uremia. Arch Intern Med 126 (1970) 812-815
9. Koch K.M., Patyna D., Shaldon S., and Werner E. Anemia of the regular hemodialysis patient and its treatment. Nephron 12 (1974) 405-419
10. Geerlings W., Morris R.W., Brunner F.P., et al. Factors influencing anaemia in dialysis patients. A special survey by the EDTA-ERA registry. Nephrol Dial Transplant 8 (1993) 585-589
11. Katzarski K.S., Charra B., Luik A.J., et al. Fluid state and blood pressure control in patients treated with long and short dialysis. Nephrol Dial Transplant 14 (1999) 369-375
12. Locatelli F., and Del Vecchio L. Dialysis adequacy and response to erythropoietic agents: what is the evidence base?. Nephrol Dial Transplant 18 Suppl. 8 (2003) viii29-viii35
13. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. ; 2009 [accessed 7.07.09].
14. Orino K., Lehman L., Tsuji Y., Ayaki H., Torti S.V., and Torti F.M. Ferritin and the response to oxidative stress. Biochem J 357 1 (2001) 241-247
15. Parkkinen J., von Bonsdorff L., Peltonen S., Gronhagen-Riska C., and Rosenlof K. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant 15 (2000) 1827-1834
16. Kovesdy C.P. Iron and clinical outcomes in dialysis and non-dialysis dependent chronic kidney disease patients. Adv Chronic Kidney Dis 16 2 (2009) 109-116
17. Paradkar P., De Domenico I., Durchfort N., Zohn I., Kaplan J., and McVey Ward D. Iron depletion limits intracellular growth in macrophages. Blood 12 3 (2008) 866-874
18. Zaritsky J., Young B., Wang H., Westerman M., Olbina G., Nemeth E., et al. A potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 4 6 (2009) 1051-1056
19. Malyszko J. Hepcidin assays: ironing out some details. Clin J Am Soc Nephrol 4 6 (2009) 1015-1016
20. Ganz T., Olbina G., Girelli D., Nemeth W., and Westerman M. Immunoassay for human serum hepcidin. Blood 112 (2008) 4292-4297
21. Mittman N., Sreedhara R., Mushnick R., Chattopadhyay J., Zelmanovic D., Vaseghi M., et al. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. Am J Kidney Dis 30 (1997) 912-922
22. Fishbane S., Shapiro W., Dutka P., Valenzuela O.F., and Faubert O.F. A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 60 (2001) 2406-2411
23. Levin A., Thompson C., Ethier J., Carlisle E., Tobe S., Mendelssohn D., et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 34 1 (1999) 125-134
24. Silverberg D.S., Wexler D., Blum M., Tchebiner J.Z., Sheps D., Keren G., et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 18 (2003) 141-146
25. Painter P., Moore G., Carlson L., Paul S., Myll J., Phillips W., et al. Effects of exercise training plus normalization of hematocrit on exercise capacity and health-related quality of life. Am J Kidney Dis 39 (2002) 257-265
26. Valderrabano F., Jofre R., and Lopez-Gomez J.M. Quality of life in end-stage renal disease patients. Am J Kidney Dis 38 (2001) 443-464
27. Pisioni R.L., Bragg-Gresham J.L., Young E.W., Akizawa T., Asano Y., Locatelli F., et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 44 (2004) 94-111
28. Popovsky M.A., and Ransil B.J. Long-term impact of recombinant human erythropoietin on transfusion support in patients with chronic renal failure. Immunohematology 12 1 (1996) 1-3
29. Aranesp (darbepoetin alfa) for injection [prescribing information]. Thousand Oaks, CA: Amgen Inc. ; 2007 [accessed 8.07.09].
30. Procrit (epoetin alfa) for injecton [prescribing information]. Thousand Oaks, CA: Amgen Inc. Distributed by Ortho Biotech Products, LP: Raritan, NJ. ; 2007 [accessed 8.07.09].
31. Epogen (epoetin alfa) for injection [prescribing information]. Thousand Oaks, CA: Amgen Inc, 2007. ; 2009 [accessed 8.07.09].
32. Nissenson A.R., Swan S.K., Lindberg J.S., et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 40 1 (2002) 110-118
33. Kaufman J.S., Reda D.J., Fye C.L., et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of veterans affairs cooperative study group on erythropoietin in hemodialysis patients. N Engl J Med 339 (1998) 578-583
34. Germain M., Ram C.V., Bhaduri S., Tang K.L., Klausner M., and Curzi M. Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review. Nephrol Dial Transplant 20 10 (2005) 2146-2152
35. Provenzano R., Bhaduri S., Singh A.K., and PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Clin Nephrol 64 2 (2005) 113-123
36. Jadoul M., Vanrenterghem Y., Foret M., Walker R., and Gray S.J. Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial Transplant 19 4 (2004) 898-903
37. Ling B., Walczyk M., Agarwal A., Carroll W., Liu W., and Brenner R. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol 63 5 (2005) 327-334
38. Macdougall I.C., and Eckardt K.U. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet 368 (2006) 947-953
39. Macdougall I.C., Padhi D., and Jang G. Pharmacology of darbepoetin alfa. Nephrol Dial Transplant 22 Suppl. 4 (2007) iv2-iv9
40. Bunn H.F. New agents that stimulate erythropoiesis. Blood 109 (2007) 868-873
41. Kimel M., Leidy N.K., Mannix S., and Dixon J. Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia? Summary of trials of cancer, HIV/AIDS, and chronic kidney disease. Value Health 11 1 (2008) 57-75
42. Regidor D.L., Kopple J.D., Kovesdy C.P., et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17 4 (2006) 1181-1191
43. Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 9 (1998) 584-590
44. Roth D., Smith R.D., Schulman G., et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 24 5 (1994) 777-784
45. Gouva C., Nikolopoulos P., Ioannidis J.P., and Siamopoulos K.C. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 66 2 (2004) 753-760
46. Drueke T.B., Locatelli F., Clyne N., et al. CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 20 (2006) 2071-2084
47. Frank H., Heusser K., Hoffken B., Huber P., Schmieder R.E., and Schobel H.P. Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients. Kidney Int 66 2 (2004) 832-840
48. Ayus J.C., Go A.S., Valderrabano F., et al. Spanish group for the study of the anemia and left ventricular hypertrophy in pre-dialysis patients. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dL. Kidney Int 68 2 (2005) 788-795
49. Wish J., Schulman K., Law A., and Nassar G. Healthcare expenditure and resource utilization in patients with anaemia and chronic kidney disease: a retrospective claims database analysis. Kidney Blood Press Res 32 2 (2009) 110-118
50. Maddux F.W., Shetty S., del Aguila M.A., Nelson M.A., and Murray B.M. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease. Ann Pharmacother 41 11 (2007) 1761-1769
51. London R., Solis A., Goldberg G.A., Wade S., and Ryu S. Health care resource utilization and the impact of anemia management in patients with chronic kidney disease. Am J Kidney Dis 40 3 (2002) 539-548
52. Papatheofanis F., Bookhart B.K., Muser E., and Piech C.T. An examination of productivity and resource utilization associated with epoetin alfa treatment in employees with predialysis chronic kidney disease. J Occup Environ Med 50 5 (2008) 584-589
53. Moyneur E., Bookhart B.K., Mody S.H., Fournier A.A., Mallett D., and Duh M.S. The economic impact of pre-dialysis epoetin alpha on health care and work loss costs in chronic kidney disease: an employer's perspective. Dis Manag 11 1 (2008) 49-58
54. Furuland H., Linde T., Ahlmen J., Christensson A., Strombom U., and Danielson B.G. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 18 2 (2003) 353-361
55. Parfrey P.S., Foley R.N., Wittreich B.H., Sullivan D.J., Zagari M.J., and Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16 7 (2005) 2180-2189
56. Singh A.K., Szczech L., Tang K.L., et al. CHOIR investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 20 (2006) 2085-2098
57. Sczcech L.A., Burnhart H.X.S., Inrig J.K., Reddan D.N., Sapp S., Califf R.M., et al. Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes. Kidney Int 74 (2008) 791-798
58. Besarab A., Frinak S., and Yee J. What is so bad about a hemoglobin of 12-13 g/dL for chronic kidney disease patients anyway?. Adv Chronic Kidney Dis 16 2 (2009) 131-142
59. Miyashita K., Tojo A., Kimura K., et al. Blood pressure response to erythropoietin injection in hemodialysis and predialysis patients. Hypertens Res 27 2 (2004) 79-84
60. Kalantar-Zadeh K., Regidor D.L., McAllister C.J., Michael B., and Warnock D.G. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 16 10 (2005) 3070-3080
61. Fletes R., Lazarus J.M., Gage J., and Chertow G.J. Suspected iron dextran-related adverse drug advents in hemodialysis patients. Am J Kidney Dis 37 (2001) 743-749
62. Spinowitz B.S., Kausz A.T., Baptista J., Noble S.D., Sothinathan R., Bernardo M.V., et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 19 (2008) 1599-1605
63. Horl W.H. Adjunctive therapy in anaemia management. Nephrol Dial Transplant 17 Suppl. 5 (2002) 56-59
64. Brewster U.C. Intravenous iron therapy in end-stage renal disease. Semin Dial 19 4 (2006) 285-290
65. Hoen B., Paul-Dauphin A., and Kessler M. Intravenous iron administration does not significantly increase the risk of bacteremia in chronic hemodialysis patients. Clin Nephrol 57 6 (2002) 457-461
66. Admas P.C., Deugnier Y., Moirand R., and Brissot P. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology 25 (1997) 162-166
67. Adamson J. Hyporesponsiveness to erythropoiesis stimulating agents in chronic kidney disease: the many faces of inflammation. Adv Chronic Kidney Dis 16 2 (2009) 76-82
68. Kamgar M., Zaldivar F., Vaziri N.D., and Pahl M.V. Antioxidant therapy does not ameliorate oxidative stress and inflammation in patients with end-stage renal disease. J Natl Med Assoc 101 4 (2009) 336-344
69. Sirover W.D., Siddiqui A.A., and Benz R.L. Beneficial hematologic effects of daily oral ascorbic acid therapy in ESRD patients with anemia and abnormal iron homeostasis: a preliminary study. Renal Failure 30 9 (2008) 884-889
70. Keven K., et al. Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients. Am J Kidney Dis 41 6 (2003) 1233-1239
71. Attallah N., Osman-Malik Y., Frinak S., and Besarab A. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Am J Kidney Dis 47 4 (2006) 644-654
72. Tarng D.C., Huang T.P., and Wei Y.H. Erythropoietin and iron: the role of ascorbic acid. Nephrol Dial Transplant 16 Suppl. 5 (2001) 35-39
73. Giancaspro V., et al. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial. J Nephrol 13 6 (2000) 444-449
74. Kletzmayr J., Mayer G., Legenstein G., et al. Anemia and carnitine supplementation in hemodialyzed patients. Kidney Int 55 Suppl. 69 (1999) 93-106
75. Labonia W.D. l-Carnitine effects on anemia in hemodialyzed patients treated with erythropoietin. Am J Kidney Dis 26 (1995) 757-764